Allergan's Q4 beats analysts' estimates: 4 insights

Parsippany-Troy Hills, NJ-based Allergan finished the 2016 fiscal year with a bang with higher than expected earnings and revenues, The Cerbat Gem reports.

Here's what you should know.

1. Allergan reported earnings per share of $3.90 for its fourth quarter, beating analysts' estimates of $3.76 EPS.

2. The company's $3.86 billion in revenues for Q4 also exceeded analysts' expectations of $3.77 billion.

3. Allergan's stock opened at $245.68 on Feb. 10, 2017.

4. The company's 52-week high is $301.32 and 52-week low is $184.50.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast